Originally published April 8.
Formal guidelines from professional medical societies now recommend that all patients with advanced lung adenocarcinomas should be tested for alterations in EGFR and ALK genes, which can help doctors then decide whether these patients will benefit from certain targeted tyrosine kinase inhibiting drugs.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
